Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Drugs Made In America Acquisition Corp. Rights (DMAAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: DMAAR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -20% | Avg. Invested days 13 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.09 - 0.17 | Updated Date 05/1/2025 |
52 Weeks Range 0.09 - 0.17 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Rights
Company Overview
History and Background
Drugs Made In America Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It was incorporated in 2020.
Core Business Areas
- Special Purpose Acquisition Company (SPAC): Drugs Made In America Acquisition Corp. is a SPAC, meaning its primary purpose is to identify and merge with a private company, effectively taking that company public.
Leadership and Structure
The company's leadership typically consists of a management team with experience in finance, operations, and the target industry. The organizational structure is generally streamlined, reflecting its focus on identifying and executing a merger.
Top Products and Market Share
Key Offerings
- Rights: Drugs Made In America Acquisition Corp. Rights (DMAQ.U) give the holder the right to purchase shares of the common stock upon completion of a business combination. Rights are typically attached to units offered during the SPAC's IPO. Market share isn't applicable to rights themselves. The 'competitors' would be other SPACs seeking mergers in the same or similar target industries.
Market Dynamics
Industry Overview
The SPAC market is dynamic, influenced by investor sentiment, regulatory changes, and the availability of attractive private companies seeking to go public. The industry can be volatile, with periods of high activity followed by corrections.
Positioning
Drugs Made In America Acquisition Corp. is positioned within the SPAC market, seeking to identify and merge with a suitable target company. Success depends on the team's ability to find a promising target and negotiate a favorable deal.
Total Addressable Market (TAM)
The TAM depends on the investment focus of the SPAC (e.g., healthcare, technology). Drugs Made In America Acquisition Corp. target market and how it is positioned within that market is not publically available.
Upturn SWOT Analysis
Strengths
- Experienced management team (assumed)
- Capital raised through IPO
- Opportunity to create value through successful merger
Weaknesses
- Dependence on identifying a suitable target
- Market volatility affecting SPAC valuations
- Potential for shareholder dilution
Opportunities
- Growing demand for alternative paths to public markets
- Attractive valuations in certain sectors
- Ability to leverage management expertise
Threats
- Increased regulatory scrutiny of SPACs
- Competition from other SPACs
- Unfavorable market conditions
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape consists of other SPACs seeking merger targets in similar industries. Competition can be intense.
Growth Trajectory and Initiatives
Historical Growth: Growth is not applicable before a merger.
Future Projections: Future growth depends entirely on the success of identifying and merging with a target company.
Recent Initiatives: Recent initiatives would include actively seeking and evaluating potential merger targets.
Summary
Drugs Made In America Acquisition Corp. is a SPAC seeking to identify and merge with a private company. Its success hinges on finding a suitable target and navigating the complexities of the SPAC market. Regulatory scrutiny and competition from other SPACs pose potential challenges. The team's experience and access to capital are key strengths.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
Disclaimers:
This analysis is based on publicly available information and general knowledge of SPACs. It is not financial advice. The information provided is for informational purposes only and should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Rights
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-02-25 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector - | Industry - | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com | ||
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.